Stock Price Prediction

ALXO stock has recently faced significant challenges, with its price dropping 16% after Phase 2 ASPEN-06 trial data failed to meet expectations, despite showing a durable clinical response and safety profile. Analysts are divided, with Jefferies downgrading the stock to "Hold" and slashing the price target to $2, citing uncertainty around 2025 readouts, while HC Wainwright maintains a bullish $5 target. The bull case hinges on potential recovery if upcoming data or strategic developments restore confidence in its lead drug pipeline.

ALXO stock is currently bearish, trading at $1.37 after a recent 16% drop due to disappointing Phase 2 ASPEN-06 trial data, which failed to meet expectations despite showing some clinical response. Insider selling, including a 1.8% reduction by the President & CSO, and Jefferies' downgrade to a $2 price target further reflect weak confidence. The stock's downward momentum and uncertainty around its lead drug candidate suggest continued pressure.